LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 67

Search options

  1. Article ; Online: Iran and the Challenge of Afghan Immigrants and Refugees With Tuberculosis.

    Abdi, Milad / Heidary, Mohsen / Mirzaei, Rasoul

    Health security

    2023  Volume 21, Issue 4, Page(s) 329–330

    MeSH term(s) Humans ; Refugees ; Iran ; Tuberculosis ; Emigrants and Immigrants
    Language English
    Publishing date 2023-05-17
    Publishing country United States
    Document type Letter
    ZDB-ID 2823049-8
    ISSN 2326-5108 ; 2326-5094
    ISSN (online) 2326-5108
    ISSN 2326-5094
    DOI 10.1089/hs.2023.0062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Ebanga™: The most recent FDA-approved drug for treating Ebola.

    Taki, Elahe / Ghanavati, Roya / Navidifar, Tahereh / Dashtbin, Shirin / Heidary, Mohsen / Moghadamnia, Marjan

    Frontiers in pharmacology

    2023  Volume 14, Page(s) 1083429

    Abstract: ... ...

    Abstract Ebolavirus
    Language English
    Publishing date 2023-03-08
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2023.1083429
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir.

    Heidary, Mohsen / Shariati, Saeedeh / Nourigheimasi, Shima / Khorami, Mona / Moradi, Melika / Motahar, Moloudsadat / Bahrami, Parisa / Akrami, Sousan / Kaviar, Vahab Hassan

    BMC infectious diseases

    2024  Volume 24, Issue 1, Page(s) 250

    Abstract: The Food and Drug Administration (FDA) has licensed many antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment options for people with multi-drug resistant HIV remain limited. Medication resistance, ... ...

    Abstract The Food and Drug Administration (FDA) has licensed many antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment options for people with multi-drug resistant HIV remain limited. Medication resistance, undesirable effects, prior tolerance, and previous interlacement incapacity to deliver new drug classes all lead to the requirement for new medication classes and drug combination therapy. Fostemsavir (FTR) is a new CD-4 attachment inhibitor medicine that was recently authorized by the United States FDA to treat HIV-1. In individuals with multidrug-resistant (MDR) HIV-1, FTR is well tolerated and virologically active. According to recent investigations, drug combination therapy can positively affect MDR-HIV. The mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of FTR has been highlighted in this review.
    MeSH term(s) United States ; Humans ; HIV Infections/drug therapy ; HIV-1 ; Anti-Retroviral Agents/therapeutic use ; Drug Combinations ; Anti-HIV Agents/adverse effects ; Organophosphates ; Piperazines
    Chemical Substances fostemsavir (97IQ273H4L) ; Anti-Retroviral Agents ; Drug Combinations ; Anti-HIV Agents ; Organophosphates ; Piperazines
    Language English
    Publishing date 2024-02-23
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2041550-3
    ISSN 1471-2334 ; 1471-2334
    ISSN (online) 1471-2334
    ISSN 1471-2334
    DOI 10.1186/s12879-024-09122-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Evaluation of immune responses to

    Darbandi, Atieh / Alamdary, Shabnam Zeighamy / Koupaei, Maryam / Ghanavati, Roya / Heidary, Mohsen / Talebi, Malihe

    Frontiers in veterinary science

    2022  Volume 9, Page(s) 903890

    Abstract: Introduction: Despite the accessibility of several live attenuated vaccines for animals, currently, there is no licensed vaccine for brucellosis in human populations. Available and confirmed animal vaccines may be harmful and considered inappropriate ... ...

    Abstract Introduction: Despite the accessibility of several live attenuated vaccines for animals, currently, there is no licensed vaccine for brucellosis in human populations. Available and confirmed animal vaccines may be harmful and considered inappropriate for humans. Thus, human vaccines for brucellosis are required. We aimed to evaluate the effects of
    Materials and methods: A systematic search was carried out in Web of Science, Embase, and PubMed/Medline databases. The following MeSH terms were applied: brucellosis, vaccine,
    Results: Of the 163 full texts that were screened, 17 articles reached to inclusion criteria. Combining the results of these trials revealed a reduction in bacterial load and colonization rate of
    Conclusion: Brucella is responsible for half-million new cases globally annually, and the lack of a proper human vaccine poses the risk of brucellosis. A variety of vaccines are used to prevent brucellosis. Subunit vaccines and recombinant human vaccines have higher safety and protective properties. Although vaccination helps brucellosis control, it does not eradicate the disease. Thus, we recommend the following strategies. (a) establishment of a registration system; (b) close monitoring of slaughterhouses, markets, and herds; (c) training veterinarians; (d) legal protection of the consequences of non-compliance with preventive measures.
    Language English
    Publishing date 2022-09-02
    Publishing country Switzerland
    Document type Systematic Review
    ZDB-ID 2834243-4
    ISSN 2297-1769
    ISSN 2297-1769
    DOI 10.3389/fvets.2022.903890
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Natural Compounds: A Hopeful Promise as an Antibiofilm Agent Against

    Shariati, Aref / Didehdar, Mojtaba / Razavi, Shabnam / Heidary, Mohsen / Soroush, Fatemeh / Chegini, Zahra

    Frontiers in pharmacology

    2022  Volume 13, Page(s) 917787

    Abstract: The biofilm communities ... ...

    Abstract The biofilm communities of
    Language English
    Publishing date 2022-07-11
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2022.917787
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Brucellosis control methods with an emphasis on vaccination: a systematic review.

    Darbandi, Atieh / Koupaei, Maryam / Navidifar, Tahereh / Shahroodian, Soheila / Heidary, Mohsen / Talebi, Malihe

    Expert review of anti-infective therapy

    2022  Volume 20, Issue 7, Page(s) 1025–1035

    Abstract: Introduction: Brucellosis is considered as one of the main zoonotic infections and a major public health concern worldwide. The aim of the present study was to evaluate various strategies for controlling brucellosis with an especial emphasis on efficacy ...

    Abstract Introduction: Brucellosis is considered as one of the main zoonotic infections and a major public health concern worldwide. The aim of the present study was to evaluate various strategies for controlling brucellosis with an especial emphasis on efficacy of vaccination.
    Areas covered: International databanks (Web of Science, PubMed, Embase) were searched for potentially relevant studies published from 1 January 2011 to 25 March 2021 using the following keywords: '
    Expert opinion: Various methods are employed to prevent and control brucellosis, such as removing sick animals by slaughtering, separating sick animals from the herd, and vaccination. Preventing, controlling, and eradicating brucellosis requires a lot of financial support, perseverance, and time. In order to conduct a detailed study, it is recommended that more studies be conducted in developing countries and different parts of the world.
    MeSH term(s) Animals ; Brucella abortus ; Brucella melitensis ; Brucellosis/prevention & control ; Humans ; Vaccination ; Zoonoses/epidemiology ; Zoonoses/prevention & control
    Language English
    Publishing date 2022-04-25
    Publishing country England
    Document type Journal Article ; Systematic Review
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1080/14787210.2022.2066521
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.

    Taki, Elahe / Soleimani, Faezeh / Asadi, Arezoo / Ghahramanpour, Hossein / Namvar, Ali / Heidary, Mohsen

    Expert review of anti-infective therapy

    2022  Volume 20, Issue 8, Page(s) 1135–1147

    Abstract: Introduction: The development of long-acting (LA) drugs has changed the management of common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva (cabotegravir/Rilpivirine) is the first LA antiretroviral injectable drug ... ...

    Abstract Introduction: The development of long-acting (LA) drugs has changed the management of common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva (cabotegravir/Rilpivirine) is the first LA antiretroviral injectable drug composed of nano-formulation of cabotegravir (CAB) and rilpivirine (RPV).
    Areas covered: In this review article, we aim to have a brief overview of results of major clinical trials that administrated Cabotegravir/Rilpivirine for patients considering the efficacy and safety profiles. Moreover, we discuss about CAB and RPV chemical structure, mechanism of action, ‎activity against drug-sensitive and -resistant HIV, and pharmacodynamics/pharmacokinetics properties.
    Expert opinion: Based on the results of the ATLAS and FLAIR trials, Cabotegravir/Rilpivirine regimen once-monthly has shown equal effectivity to oral combination antiretroviral therapy (cART) in maintaining HIV-1 suppression in patients. Furthermore, ATLAS-2 M study revealed the non-inferiority of Cabotegravir/Rilpivirine regimen every 8 weeks compared to every 4 weeks. The injectable LA ART reduces the number of treatment intake as well as increases adherence, especially in patients with HIV-related stigma. Administration of extended-release agents probably minimize the risk of treatment-related toxicity and resistance related to sub-optimal adherence to oral ART, so Cabotegravir/Rilpivirine can be suggested as a suitable alternative for HIV infection control in current era.
    MeSH term(s) Anti-HIV Agents/adverse effects ; Anti-Retroviral Agents/therapeutic use ; Diketopiperazines ; Drug Combinations ; HIV Infections/drug therapy ; Humans ; Pharmaceutical Preparations ; Pyridones ; Rilpivirine/adverse effects
    Chemical Substances Anti-HIV Agents ; Anti-Retroviral Agents ; Diketopiperazines ; Drug Combinations ; Pharmaceutical Preparations ; Pyridones ; cabotegravir, rilpivirine drug combination ; Rilpivirine (FI96A8X663) ; cabotegravir (HMH0132Z1Q)
    Language English
    Publishing date 2022-06-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1080/14787210.2022.2081153
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment.

    Heidary, Mohsen / Shirani, Maryam / Moradi, Melika / Goudarzi, Mehdi / Pouriran, Ramin / Rezaeian, Tayebe / Khoshnood, Saeed

    European journal of microbiology & immunology

    2022  

    Abstract: Early diagnosis of tuberculosis (TB), followed by effective treatment, is the cornerstone of global TB control efforts. An estimated 3 million cases of TB remain undetected each year. Early detection and effective management of TB can prevent severe ... ...

    Abstract Early diagnosis of tuberculosis (TB), followed by effective treatment, is the cornerstone of global TB control efforts. An estimated 3 million cases of TB remain undetected each year. Early detection and effective management of TB can prevent severe disease and reduce mortality and transmission. Intrinsic and acquired drug resistance of Mycobacterium tuberculosis (MTB) severely restricted the anti-TB therapeutic options, and public health policies are required to preserve the new medications to treat TB. In addition, TB and HIV frequently accelerate the progression of each other, and one disease can enhance the other effect. Overall, TB-HIV co-infections show an adverse bidirectional interaction. For HIV-infected patients, the risk of developing TB disease is approximately 22 times higher than for persons with a protective immune response. Analysis of the current TB challenges is critical to meet the goals of the end TB strategy and can go a long way in eradicating the disease. It provides opportunities for global TB control and demonstrates the efforts required to accelerate eliminating TB. This review will discuss the main challenges of the TB era, including resistance, co-infection, diagnosis, and treatment.
    Language English
    Publishing date 2022-04-14
    Publishing country Hungary
    Document type Journal Article ; Review
    ZDB-ID 2652327-9
    ISSN 2062-8633 ; 2062-509X
    ISSN (online) 2062-8633
    ISSN 2062-509X
    DOI 10.1556/1886.2021.00021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Epidemiology of HBV-HCV Coinfection Among Iranian Patients: a Systematic Review and Meta-Analysis.

    Anvari, Hamed Z / Binabaj, Maryam M / Asadi, Arezoo / Abdi, Milad / Shakiba, Abolfazl / Heidary, Mohsen / Sholeh, Mohammad

    Clinical laboratory

    2023  Volume 69, Issue 11

    Abstract: Introduction: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of hepatitis, an important disease affecting millions of people worldwide. The present study aimed to estimate the prevalence of HBV-HCV coinfection in Iran ... ...

    Abstract Introduction: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of hepatitis, an important disease affecting millions of people worldwide. The present study aimed to estimate the prevalence of HBV-HCV coinfection in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.
    Methods: We used MEDLINE/PubMed, Web of Science, SCOPUS, Google Scholar, and 1 Persian database (Scientific Information Database) for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed based on the city, publication time, enrollment time, number of patients, gender, mean age, and HBV/HCV diagnosis method. The analysis was carried out using R (version 4.2.1) and the metafor package (version 3.8.1).
    Results: In total, 2,072 studies were found through databases: PubMed/Medline (n = 224), Scopus (n = 1,092), Web of Science (n = 394), Google Scholar (n = 272), and Scientific Information Database (n = 90). Overall, nine studies with 1,964 male and 1,909 female patients (age average = 38.1) were included in the analysis. The observed proportion ranged from 0.004 to 0.273. The estimated average proportion was μ = 0.040 (95% CI: 0.016 to 0.101). Therefore, the average outcome differed significantly from zero (z = -6.330, p < 0.001).
    Conclusions: HBV/HCV coinfection is a challenging and crucial medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. There is a heterogeneous distribution pattern of HBV/HCV infection between Iran's provinces, indicating the necessity of continuous prevention and control measurements and the implementation of further epidemiologic studies for collecting reliable data on HBV/HCV prevalence in different parts of Iran.
    MeSH term(s) Humans ; Male ; Female ; Hepatitis B virus ; Iran/epidemiology ; Carcinoma, Hepatocellular/complications ; Coinfection/epidemiology ; Liver Neoplasms/complications ; Hepatitis B/complications ; Hepatitis C/diagnosis ; Hepatitis C/epidemiology ; Hepatitis C/complications ; Hepacivirus ; Prevalence
    Language English
    Publishing date 2023-11-10
    Publishing country Germany
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 1307629-2
    ISSN 1433-6510 ; 0941-2131
    ISSN 1433-6510 ; 0941-2131
    DOI 10.7754/Clin.Lab.2023.230503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Fatal vanishing bile duct syndrome in Iranian patient with Hodgkin's lymphoma.

    Shokri, Fazlollah / Shariati, Aref / Veisari, Arash Kazemi / Kianezhad, Amirhossein / Sheidaei, Somayeh / Alamian, Ali Asghar / Sadeghi, Hossein / Heidary, Mohsen

    Clinical case reports

    2023  Volume 11, Issue 7, Page(s) e7671

    Abstract: Vanishing bile duct syndrome (VBDS) has been postulated that may be related to Hodgkin's lymphoma (HL). In the present study, we present a 75-year-old male patient with HL who received chemotherapy but has not received any radiotherapy. The patient's ... ...

    Abstract Vanishing bile duct syndrome (VBDS) has been postulated that may be related to Hodgkin's lymphoma (HL). In the present study, we present a 75-year-old male patient with HL who received chemotherapy but has not received any radiotherapy. The patient's condition worsened in further days, and he died with the diagnosis of cirrhosis and hepatic failure.
    Language English
    Publishing date 2023-07-19
    Publishing country England
    Document type Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.7671
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top